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Internal tandem duplication (ITD) of fms-like tyrosine kinase 3 (FLT3) is one of the 
most common mutations in acute myeloid leukemia (AML), occurring in nearly 30% 
of cases. FLT3-ITD involves in-frame duplication of 3-400 base-pairs at the juxta-
membrane, resulting in ligand-independent activation of FLT3 signaling. Downstream 
effectors include activation of STAT5 via SRC kinase, phosphorylation of FOXO3A, 
down-regulation of the equilibrative nucleoside transporter 1 (ENT1) for cytarabine, 
and induction of reactive oxygen species (ROS) production. These aberrant signals 
result in increased DNA damage and defective repair, increased cellular proliferation 
and resistance to apoptosis.  
 
Induction of ROS and DNA damage in FLT3-ITD AML has led to investigation of 
their mechanistic link and exploration of potential therapeutic targets. By examining 
gene expression associated with DNA repair in primary AML samples, BRCA2 
expression was shown to be down-regulated in FLT3-ITD AML when compared with 
AML with wild-type FLT3 as well as normal hematopoietic cells. BRCA2 is an 
important protein in mediating homologous recombination (HR), providing a possible 
explanation for defective DNA damage response (DDR) in this AML subtype. A 
 iii 
double-stranded break (DSB) DNA repair assay was used to measure the fidelity of 
DSB repair, either via error-free HR or error-prone non-homologous end joining 
(NHEJ). The results showed that HR was down-regulated in murine Ba/F3 cells 
transduced with FLT3-ITD while NHEJ remained active.  
 
DDR pathway as a target for therapeutic intervention in human cancers is exemplified 
by the use of poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in BRCA 
mutant breast and ovarian cancers. In Ba/F3 FLT3-ITD cells and knockin Flt3 ITD/+ 
Npm1 c/+ mouse leukemic cells, PARPi Olaparib suppressed leukemia growth in vitro. 
Combination of chemotherapy and Olaparib worked synergistically to eradicate 
leukemic cells in MOLM-13 murine xenograft model. Biochemically, Olaparib 
inhibited base excision repair and increased the DSB damage. Olaparib also increased 
intracellular ROS, resulting in positive feedback that accentuated DNA damage. To 
identify potential therapeutic targets that may be exploited in combination treatment 
with Olaparib, a DDR shRNA library screening was performed. Potential candidate 
genes included those associated with checkpoint factors and DNA replication factors, 
for instance, Atr kinase and members of the Family B DNA Polymerase.  
  
In summary, FLT3-ITD AML showed defective HR and higher levels of intracellular 
ROS and DSB, and Olaparib induced genomic instability and apoptosis. Targeting 
defective DNA repair in FLT3-ITD AML using PARPi might be considered as a novel 





I declare that this thesis represents my own work, except where due acknowledgement 
is made, and that has not been previously included in a thesis, dissertation or report 






















I would like to express my sincerest gratitude to my supervisors, Prof. Anskar Y. H. 
Leung and Prof. Eric C. W. So. It has been a value experience to learn the perspectives 
and importance of leukemia research from clinical and basic science studies. 
 
I would like to thank my dearest friends and labmates in HKU: Dr. Alvin Ma, Dr. 
Himm Man, Dr. Alex He, Dr. Yuhan Guo, Dr. Xiangguo Shi, Dr. Christa Ho, Dr. Eric 
Ho, Dr. Stephen Lam, Dr. Qingyun Wu, Dr. Ning Yang, Dr. Wan Liu, Miss Chae yin 
Cher, Mr. Harry Wong, Miss Toni Man, Miss Bowie Cheng, Mr. Leo Kan, Mr. Siyang 
Wang, Miss Lulu Wang, and friends and labmates in KCL: Dr. Bernd Zeisig, Miss 
Amanda Wilson, Dr. Michael Cheung, Dr. Tsz Kan Fung, Dr. Priscilla Lau, Dr. Rick 
Kong, Dr. Jackie Chen, Dr. Marco Saia, Dr. Lu Zhao, Dr. Jennifer Lynch, Dr. Haoli 
Li, Dr. Yongrang Kim, Dr. Bohan Stanojevic, Mr. Ray Tsai, Miss Siyi Zhang, Miss 
Claire Lynn and Mr. Mickey Wong for their continuous support and inspiration. In 
particular, my sincere thanks to Miss Claire Lynn for her help with bioinformatics 
analysis of the shRNA screening.  
 
I would like to thank Dr. Jerome Tamburini (Institut Cochin, Université Paris 
Descartes, Paris, France) for providing the Ba/F3 FLT3-ITD cell line, Dr. Johannes 
Zuber’s group (Research Institute of Molecular Pathology, Vienna) for sharing their 
latest protocol on shRNA library screening and Dr. George S Vassiliou (Sanger 
Institute, UK) for providing the Flt3 ITD/+ x Npm1 c/+ leukemic cells.
 
Last but not least, I would like to express my deepest gratitude to my family and 
friends for their continuous support and encouragement. 
 vi 
List of Publications and Award  
Publications with my contribution during the PhD study: 
1. Man, C. H., Fung, T. K., Wan, H., Cher, C. Y., Fan, A., Ng, N., Ho, C., Wan, T. 
S., Tanaka, T., So, C. W., Kwong, Y. L. & Leung, A. Y. Suppression of SOX7 by 
DNA methylation and its tumor suppressor function in acute myeloid leukemia. 
Blood 125, 3928-3936, doi:10.1182/blood-2014-06-580993 (2015). 
 
2. Hou, J., Luo, T., Ng, K. L., Liang, R., Leung, A. Y. & Sun, D. Characterization of 
drug effect on leukemia cells through single cell assay with optical tweezers and 
dielectrophoresis. IEEE Trans Nanobioscience, doi:10.1109/TNB.2016.2616160 
(2016). 
 
3. Lam, S. S., Ho, E. S., He, B. L., Wong, W. W., Cher, C. Y., Ng, N. K., Man, C. 
H., Gill, H., Cheung, A. M., Ip, H. W., So, C. C., Tamburini, J., So, C. W., Ho, D. 
N., Au, C. H., Chan, T. L., Ma, E. S., Liang, R., Kwong, Y. L. & Leung, A. Y. 
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD 










List of Figures 
Figure 1.1 Examples of DNA damage response pathways in mammalian cells. .................................... 3 
Figure 1.2. DSB repair pathways in mammalian cells. ........................................................................... 4 
Figure 1.3 A schematic diagram of the human FLT3 receptor tyrosine kinase. ..................................... 9 
Figure 1.4 A schematic diagram showing downstream signaling that occurred upon activation of 
FLT3. ..................................................................................................................................................... 10 
Figure 1.5 A schematic diagram showing the reported mechanism of elevated intracellular ROS via 
FLT3-ITD signaling. ............................................................................................................................... 14 
Figure 4.1 Gene expression profile of DNA repair genes in primary AML patients. ............................. 29 
Figure 4.2 BRCA2 expression profile from GSE15434. .......................................................................... 30 
Figure 4.3 BRCA2 expression of human AML cell lines. ........................................................................ 31 
Figure 4.4 Gene expression profile of DNA repair genes in human AML cell lines after treatment of 
FLT3 inhibitor, quizartinib. ................................................................................................................... 32 
Figure 4.5 Brca2 expression in Ba/F3 FLT3-ITD isogenic model. .......................................................... 34 
Figure 4.6 Principle of the Traffic Light Reporter (TLR) assay. ............................................................. 36 
Figure 4.7 Representative flow plot of the TLR reporter assay. ........................................................... 37 
Figure 4.8 Statistical analysis of the TLR assay. ................................................................................... 38 
Figure 5.1 Cell proliferation assay of inhibitors targeting DNA repair proteins. .................................. 40 
Figure 5.2 Analysis of g-H2AX level in Ba/F3 FLT3-ITD cells treated with Olaparib by immunoblot 
analysis and immunofluorescence microscopy. ................................................................................... 43 
Figure 5.3 Diagrammatic illustration of neutral comet assay analysis using OpenComet Software. .. 44 
Figure 5.4 Neutral comet assay in Ba/F3 FLT3-ITD cells treated with Olaparib. .................................. 45 
Figure 5.5 Intracellular ROS measurement of Ba/F3 FLT3-ITD cells treated with Olaparib. ................ 47 
Figure 5.6 In vivo drug treatment of Olaparib and chemotherapy in MOLM-13 xenograft model. ..... 48 
Figure 6.1 Construction of mouse DDR shRNA library. ......................................................................... 50 
Figure 6.2 Immunophenotype analysis of leukemic mice transplanted with spleen cells recovered 
from Flt3ITD/+ Npm1c+/+ knockin mouse. ................................................................................................ 52 
Figure 6.3 Immunophenotype analysis of primary murine Flt3 ITD/+ Npm1 c/+ cell line. ......................... 53 
Figure 6.4 Colony formation assay of leukemic cells of MLL-AF9 or Flt3ITD/+ Npm1c/+ treated with 
Olaparib for 5 days in methyl cellulose. ............................................................................................... 54 
Figure 6.5 Experimental scheme of in vivo shRNA library screening. ................................................... 55 
Figure 6.6 Information of DNA sample for Miseq. ............................................................................... 57 
Figure 6.7 FASTQC plot of the Miseq sequencing run. ......................................................................... 58 
Figure 6.8 Alignment result of Miseq run to unique hairpin sequences. .............................................. 59 
Figure 6.9 Overall distribution of probability of gene dropout in the shRNA screen. ........................... 61 
Figure 6.10 Distribution of unique hairpin dropouts. ........................................................................... 62 
Figure 6.11 Pie chart of overall distribution of dropout genes categorized by their role in DNA 
damage response pathways. ............................................................................................................... 64 









Appendix 1 Culture conditions of human AML cell lines. ..................................................................... 71 
Appendix 2 List of primers used for RT-QPCR. ...................................................................................... 71 
Appendix 3 List of antibodies used. ...................................................................................................... 72 
Appendix 4 Clinical trials involving DDR inhibitors ............................................................................... 72 
Appendix 5 Miseq sequencing run samples. ........................................................................................ 74 
Appendix 6 Candidate dropout gene list specific to Olaparib treatment. ............................................ 75 






















List of abbreviations 
Abbreviation Full name 
2HG D-2-hydroxyglutarate 
8-OHdG 8-hydroxy-2’-deoxyguanosine 
8-oxoG 8-hydroxyguanine  
a-KG alpha-ketoglutarate  
Alt-NHEJ alternative nonhomologous end-joining 
AML acute myeloid leukemia  
APL acute promyelocytic leukemia 
ATM ataxia telangiectasia mutated 
Atr ATM and rad3-related 
BER base excision repair 
BM bone marrow 
cDNA complementary DNA  
CG cytogenetic  
ChIP chromatin immunoprecipitation 
CML chronic myelogenous leukemia  
CMML chronic myelomonocytic leukemia  
D2HG D-2-hydroxyglutarate 
DDR DNA damage response 
dGFP defective GFP  
Diff. difference 
DMSO dimethylsulfoxide 
DNA-PKcs DNA-dependent protein kinase catalytic subunit 
DR DNA repair 
DSB double-stranded break 
DSBR double stranded breaks repair 
ENT1 equilibrative nucleoside transporter 1 
FA fanconi anemia 
FapyG formamidopyrimidines 
FBS fetal bovine serum  
FLT3 fms-like tyrosine kinase 3  
g-H2AX gamma-H2AX 
H2DCFDA 2’7’-dichlorodihydro-fluorecein diacetate  
HBSS Hanks’ Balanced Salt Solution 
HR homologous recombination 
HSCT haematopoietic stem cell transplantation  
HSPC hematopoietic stem and progenitor cells  
IDH1 isocitrate dehydrogenase 1 
IDH2 isocitrate dehydrogenase 2  
ITD Internal tandem duplication 
LIG3 DNA ligase IIIa 
 x 
LSC leukemia stem cell 
MDS myelodysplastic syndrome 
MMEJ microhomology-mediated end joining 
MMR mismatch repair 
MNC mononuclear cell  
MRE11 meiotic recombination 11 homolog A  
MRN MRE11/RAD50/NSB1  
NAC N-acetyl cysteine  
NAPDH nicotinamide adenine dinucleotide phosphate-oxidases 
NER nucleotide excision repair 
NHEJ non-homologous end joining 
NOX4 NAPDH oxidase 4 
NSG NOD/SCID/IL2Rg−/−  
Ola. Olaparib 
ORF open reading frame 
PARP poly (ADP-ribose) polymerase 
PARPi PARP inhibitor 
PB peripheral blood  
PBSC peripheral blood stem cell 
Pdrop probability of hairpin dropout 
Pdrop of O-V probability of hairpin dropout of Olaparib-treated 
minus vehicle  
pHi intracellular pH  
phox phagocytic oxidase 
ROS reactive oxygen species 
RTK receptor tyrosine kinase 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel 
electrophoresis  
SOP standard operating procedure  
SSB single-stranded break  
TKD tyrosine kinase domain 
TLR Traffic Light Reporter  
TLS translesion repair 
TP53BP1 p53-binding protein 1  
Veh. vehicle 
WB Whole Blood  






Table of Contents 
Declaration .......................................................................................................... iv 
Acknowledgements ............................................................................................... v 
List of Publications and Award ............................................................................. vi 
List of Figures ...................................................................................................... vii 
Appendix ........................................................................................................... viii 
List of abbreviations ............................................................................................ ix 
Chapter 1. Introduction ......................................................................................... 1 
1.1 Background of acute myeloid leukemia .................................................................. 1 
1.2 Aberrant DNA damage repair mechanism in myeloid malignancies ........................ 2 
1.2.1 Introduction ......................................................................................................................... 2 
1.2.2 DSB repair mechanism in mammalian cells ......................................................................... 2 
1.2.3 DNA repair defect in chronic myelogenous leukemia ......................................................... 5 
1.2.4 RAS are responsible for elevated ROS and DNA damage in myeloid malignancies ............. 6 
1.2.5 IDH1/2 mutation impairs homologous recombination ....................................................... 6 
1.2.6 HR deregulation in translocations involving transcription factors ...................................... 7 
1.3 The role of internal tandem duplication of Fms-Like Tyrosine kinase 3 in AML ....... 8 
1.3.1 Introduction to Fms-Like Tyrosine kinase 3 ......................................................................... 8 
1.3.2 Internal tandem duplication of Fms-Like Tyrosine kinase 3 .............................................. 11 
1.3.3 Clinical strategies to prolong remission are lacking .......................................................... 11 
1.4 Aberrant DNA damage response signaling in FLT3-ITD AML .................................. 12 
1.4.1 Elevated intracellular ROS is the cause of genomic instability in FLT3-ITD AML ............... 12 
1.4.2 DSB repair is impaired in FLT3-ITD AML ............................................................................ 13 
1.4.3 Targeting DNA repair defect in FLT3-ITD AML ................................................................... 15 
Chapter 2. Study Objectives ................................................................................ 16 
Chapter 3 Materials and Methods ....................................................................... 17 
3.1 Primary sample processing ................................................................................... 17 
3.2 Culture and maintenance of cell lines ................................................................... 18 
3.2.1 Human acute myeloid leukemia cell lines ......................................................................... 18 
3.2.2 Ba/F3 cell line and its derivatives ...................................................................................... 18 
3.3 In vitro drug treatment ......................................................................................... 18 
3.4 RNA extraction and reverse transcription polymerase chain reaction ................... 19 
3.4.1 RNA extraction ................................................................................................................... 19 
3.4.2 Reverse transcription polymerase chain reaction ............................................................. 20 
3.5 Real-time quantitative PCR (RT-QPCR) ................................................................. 20 
3.6 Western Blot ........................................................................................................ 20 
3.7 Immunofluorescence Microscopy ......................................................................... 21 
3.8 Neutral comet assay ............................................................................................. 21 
3.9 General flow cytometry experiments ................................................................... 22 
3.9.1 Intracellular reactive oxidative species (ROS) level measurement .................................... 22 
3.9.2 Immunophenotypic analysis of primary murine cells ........................................................ 22 
3.10 Lentivirus packaging ........................................................................................... 23 
 xii 
3.11 Traffic Light Reporter (TLR) assay ....................................................................... 23 
3.12 DNA damage response (DDR) shRNA library screening ....................................... 24 
3.12.1 Cloning of DDR shRNA library plasmids ........................................................................... 24 
3.12.2 Experimental Scheme of DDR shRNA library screening ................................................... 24 
3.12.3 Preparation of sequencing library for MiSeq ................................................................... 25 
3.12.4 Bioinformatics analysis .................................................................................................... 25 
3.13 In vivo drug treatment of Olaparib and chemotherapy drugs in MOLM-13 
xenograft model ........................................................................................................ 26 
3.14 Statistical analysis .............................................................................................. 26 
Chapter 4. Homologous recombination in FLT3-ITD AML was affected with 
possible mechanistic linkage to down-regulation of BRCA2. ................................ 27 
4.1 Introduction ......................................................................................................... 27 
4.2 Down-regulation of BRCA2 in FLT3-ITD primary AML samples .............................. 27 
4.3 FLT3-ITD signaling was responsible for the suppression of BRCA2 expression ....... 28 
4.4 Homologous recombination activity was decreased in FLT3-ITD cells ................... 33 
Chapter 5. Targeting FLT3-ITD AML with PARP inhibitor ...................................... 39 
5.1 Introduction ......................................................................................................... 39 
5.2 PARP inhibitors selectively targeted FLT3-ITD AML in vitro by cell proliferation 
assay .......................................................................................................................... 39 
5.3 FLT3-ITD cells showed higher basal level of double-stranded DNA breaks that was 
accentuated by Olaparib. ........................................................................................... 41 
5.4 Elevated ROS level modulated sensitivity of FLT3-ITD to PARP inhibitor ............... 46 
5.5 Combination of PARP inhibitors and chemotherapy ............................................. 46 
Chapter 6 Screening of synthetic lethal candidate of DDR genes with PARP 
inhibitors by shRNA library screen ....................................................................... 49 
6.1 Methodology ....................................................................................................... 49 
6.2 Characterization and generation of Flt3ITD Npm1c+ cell line ................................... 49 
6.3 Experimental scheme of DDR shRNA screening in vivo ......................................... 51 
6.4 Basic bioinformatics filtering of the MiSeq run ..................................................... 56 
6.5 Dropout analysis of shRNA library screening ........................................................ 60 
Chapter 7. Summary and Discussions .................................................................. 65 
Appendix ............................................................................................................ 71 
Adapted from {Hengel, 2017 #133} ..................................................................... 73 
Reference ............................................................................................................ 77 
 
 1 
Chapter 1. Introduction 
1.1 Background of acute myeloid leukemia 
Acute myeloid leukemia (AML) is a heterogeneous group of diseases with diverse 
clinicopathologic features, cytogenetic (CG) abnormalities and genetic mutations, 
sharing in common an abnormal increase in myeloblasts in peripheral blood (PB) and 
bone marrow (BM) 1. According to the World Health Organization (WHO) 
classification, diagnosis of AML is defined by the presence of more than 20% 
myeloblasts either in the BM or PB, with the exception of t(8;21), inv(16) and t(15;17) 
in which the presence of specific CG abnormalities are sufficient for diagnosis 2.  
 
Despite the heterogeneity, treatment of AML has been uniform and unchanged in the 
past 4 decades 3-6. Induction chemotherapy, known as the “7+3” regimen, comprises 
concurrent treatment with cytarabine (day 1-7) and daunorubicin or equivalence (day 
1-3). Following an initial remission (blasts ≤ 5%), patients receive either consolidation 
chemotherapy (high dose cytarabine) or allogeneic haematopoietic stem cell 
transplantation (HSCT). However, disease relapse is a major cause of treatment failure 
and only 30-40% can survive long-term. For elderly patients unfit for conventional 




1.2 Aberrant DNA damage repair mechanism in myeloid 
malignancies 
1.2.1 Introduction 
Our genomic DNA is constantly exposed to genotoxic stress such as replication errors, 
reactive oxidative species (ROS) and ultraviolet radiation (Fig 1.1) 8. Single-strand 
DNA breaks (SSB) are repaired by base excision repair (BER), nucleotide excision 
repair (NER) and mismatch repair (MMR) 9. If unrepaired, SSB or crosslinks can 
induce replication fork collapse and result in double-stranded break (DSB) during 
DNA replication 10-12. Cancer therapies such as ionization radiation, alkylating agents, 
topoisomerase II inhibitors or excessive ROS may also induce DSB 13,14. DNA damage 
response (DDR) is strictly regulated to maintain genomic integrity and protect cells 
from genomic stress 15. When DNA damage occurs, cells respond by an orchestrated 
network of signals that sense and repair the damage. At the same time, cell-cycle 
checkpoints are activated to allow time for DDR and avoid inadvertent replication of 
damaged DNA. If the damage is not repaired, these checkpoints can trigger cellular 
senescence or apoptosis 16,17 .  
 
1.2.2 DSB repair mechanism in mammalian cells 
Three major repair pathways of DSB have been described in mammals, viz. BRCA-
mediated error-free homologous recombination (HR), DNA-dependent protein kinase 
(DNA-PK)-mediated error-prone non-homologous end joining (NHEJ) and a less 
















Figure 1.1 Examples of DNA damage response pathways in mammalian cells.  
DNA damage agents induce a spectrum of DNA lesions, which can be repaired by 
distinct and specific DNA repair pathways with various degrees of fidelity. The 













Figure 1.2. DSB repair pathways in mammalian cells. 
DNA double-stranded breaks can be repaired by 3 major pathways, including 
homologous recombination (HR), non-homologous end joining (NHEJ) and 
alternative non-homologous end joining (Alt-NHEJ). Key components of these 




sister chromatid as template for accurate DSB repair and is only active in proliferating 
cells during late S and G2 phases of cell cycle. NHEJ occurs throughout cell cycle but 
mostly during G1 in both proliferating and quiescent cells 21. Emerging evidences 
demonstrate a PARP1-dependent and microhomology-mediated end joining (MMEJ), 
also known as alternative nonhomologous end joining (Alt-NHEJ) 22. Mechanistically, 
MMEJ and HR share the same MRE11-dependent initial end resection step and both 
repair pathways occur during S/G2 phase of cycle 23.  
 
DSBs are rapidly detected by the MRE11/RAD50/NSB1 (MRN) complex or the 
Ku70/80 complex, followed by phosphorylation and activation of the apical sensor 
kinases ataxia telangiectasia mutated (ATM) and DNA-dependent protein kinase 
catalytic subunit (DNA-PKc) respectively 24. Activated apical sensor kinases 
phosphorylate the serine139 residue of histone variant gamma-H2AX (g-H2AX) at 
the DSB site. Subsequently, DNA damage mediators are recruited, for instance, TP53-
binding protein 1 (TP53BP1) in NHEJ and BRCA1 in HR 25,26. Defective DDR has 
been shown to play an important role in the pathogenesis of myeloid malignancies 
driven by BCR-ABL fusion and NRAS activating mutations18,27-39 and more recently in 
AML carrying IDH1/2 mutations and specific gene function arising from translocation 
40-42.  
 
1.2.3 DNA repair defect in chronic myelogenous leukemia 
Defective DDR has been reported in chronic myelogenous leukemia (CML) 31,35,36. 
CML is caused by a balanced translocation between chromosome 9 and 22, resulting 
in the formation of oncogenic fusion protein BCR-ABL 36. The latter is a constitutively 
active tyrosine kinase that activates cell proliferation and protects them from apoptosis 
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35. Recent reports showed that it also induced ROS production and caused DSB and 
genomic instability 31-34. On the other hand, DDR by HR was defective in CML cells 
27,28,33. Mutation analysis of HR related proteins showed that half of them belonged to 
G/C à A/T transitions, suggesting oxidative DNA damage due to ROS 43. 
 
1.2.4 RAS are responsible for elevated ROS and DNA damage in myeloid malignancies 
Activating NRAS and KRAS mutations at codons 12, 13 and 61 have been shown to 
compromise its GTPase activity, leading to a constitutively active and GTP-bound 
state 38. N- & K-RAS mutations, mostly at codons 12 and 13 occur in 66% of chronic 
myelomonocytic leukemia (CMML) 39 whereas 30% of AML carry NRAS mutations 
38 . Overexpression of NRAS-G12D and BCL2 driven by MRP8 promoter in a double 
transgenic mouse model led to increase in DNA damage and NHEJ repair errors 37. 
RAC1, an essential component of the NADPH oxidase complex, was required for ROS 
production in the NRAS/BCL2 mice. Mechanistically, RAC1 was a downstream target 
of RAS activation 44. DSB and NHEJ repair error could be ameliorated by feeding the 
mice with anti-oxidant N-acetyl cysteine (NAC), a scavenger of ROS, suggesting that 
the RAS/RAC1 pathways and ROS could be a therapeutic target for RAS mutated 
myeloid malignancies.  
 
1.2.5 IDH1/2 mutation impairs homologous recombination 
Isocitrate dehydrogenase 1 and 2 (IDH1/2) are frequently mutated in AML and 
myelodysplastic syndrome (MDS). Wild-type IDHs catalyze oxidative 
decarboxylation of isocitrate to alpha-ketoglutarate (a-KG) in citric acid cycle. 
Mutations of IDH1 at codon 132 and IDH2 at codon 140 and 172 conferred new 
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substrate specificity and enzyme activity and the mutant enzymes converted a-KG to 
the oncometabolite D-2-hydroxyglutarate (2HG) 45,46. The latter inhibited TET family 
proteins, thereby impeding DNA methylation 45. In idh1-R132Q knockin mouse 
model, the mutant idh1 down-regulated Atm by altering histone methylation, 
impairing DNA repair via a TET2-independent pathway 42. Recently, IDH1 R132H 
and IDH2 R172K knockin cell lines showed defective HR and increased sensitivity to 
PARP inhibitor (PARPi), reminiscent of synthetic lethality in BRCA1/2 mutant breast 
and ovarian cancers 40. The phenotype could be restored by inhibitors against mutant 
IDH1, proving the pathogenetic role of mutant IDH1/2 in defective DDR.  
 
1.2.6 HR deregulation in translocations involving transcription factors 
Chromosomal translocation resulting in fusion genes with aberrant transcription factor 
function is a common feature in AML 1. RUNX1-RUNX1T1 and PML-RARa fusion 
proteins have been shown to suppress expression of key HR-associated genes and 
hence defective HR 41. Mouse leukemic cells carrying these fusions were sensitive to 
PARPi, in contrast to those carrying MLL-AF9 fusion. Mechanistically, Hoxa9 that 
was downstream to MLL-AF9, activated expression of HR-associated genes. 
Pharmacological inhibition or genetic knockout of Hoxa9 gene impaired DDR and re-
sensitized MLL-AF9 leukemic cells to PARPi. Moreover, combination of PARPi with 
DNMT inhibitors or chemotherapies showed significant anti-leukemic effects in both 
mouse and human leukemia cells carrying MLL-AF9, providing important leads for 
clinical trials 47.  
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1.3 The role of internal tandem duplication of Fms-Like Tyrosine 
kinase 3 in AML 
1.3.1 Introduction to Fms-Like Tyrosine kinase 3 
Fms-like tyrosine kinase 3 (FLT3) encodes a 933-amino-acids class III receptor 
tyrosine kinase (RTK) and is located on chromosome 13q12, consisting of 24 exons 
48,49. FLT3 is preferentially expressed in human CD34+ hematopoietic stem and 
progenitor cells (HSPC) where it provides signals for survival, proliferation and 
differentiation. The FLT3 receptor comprises i) five extracellular immunoglobulin-
like domain for ligand binding and receptor dimerization in the N-terminus; ii) a 
transmembrane domain; iii) a juxtamembrane domain; and iv) two intracellular 
tyrosine kinase domains (TKD1 and TKD2) at the C-terminus (Fig. 1.3) 50,51. FLT3 
protein undergoes glycosylation in endoplasmic reticulum and Golgi apparatus to 
promote its translocation to the cell membrane 52,53. Upon binding to its ligand, FLT3 
undergoes dimerization, auto-phosphorylation and activation of the downstream 
effectors including PI3K (phosphoinositide-3-kinase), JAK-STAT and RAS pathways 










Figure 1.3 A schematic diagram of the human FLT3 receptor tyrosine kinase.  
The positions of internal tandem duplication (ITD) mutation and tyrosine kinase 









Figure 1.4 A schematic diagram showing downstream signaling that occurred 
upon activation of FLT3.  
The binding of the FLT3 ligand (FL) to the receptor triggered the formation of FLT3 
homodimer. The activation of FLT3 induced signal transduction via PI3K 
(phospatidylinositol-3-kinase), JAK-STAT and RAS pathways, resulting in enhanced 




1.3.2 Internal tandem duplication of Fms-Like Tyrosine kinase 3 
Internal tandem duplication (ITD) of FLT3 is one of the most common mutations in 
AML, particularly in AML with normal cytogenetics, t(6;9) translocation and acute 
promyelocytic leukemia (APL) 57. FLT3-ITD involves in-frame duplication of 3-400 
base-pairs at the juxta-membrane or TKD1 domains, resulting in constitutive 
activation of FLT3 signaling independent of its ligand. Downstream effectors of FLT3 
include activation of STAT5 via SRC kinase, phosphorylation of FOXO3A, down-
regulation of the equilibrative nucleoside transporter 1 (ENT1) for cytarabine, and 
induction of ROS production. These aberrant signals result in increased cellular 
proliferation, resistance to apoptosis and defective DDR. FLT3-ITD AML showed 
higher relapse risk after conventional treatment and hence inferior outcome. Larger 
size of ITD, higher allelic burden and multiple ITD mutations also indicated worse 
prognosis 58-60. 
 
1.3.3 Clinical strategies to prolong remission are lacking 
Clinical trials using multi-kinase or specific FLT3 inhibitors including sorafenib and 
quizartinib (formerly AC220) have been effective in clearing myeloblasts from PB 
and BM but responses are typically transient. Proposed mechanisms of drug resistance 
include emergence of TKD mutations (FLT3/ITD/TKD) 61,62, over-expression of FLT3 
signaling proteins 63, protection of leukemia stem cells (LSC) in niche 64 and an 




1.4 Aberrant DNA damage response signaling in FLT3-ITD AML 
1.4.1 Elevated intracellular ROS is the cause of genomic instability in FLT3-ITD AML 
FLT3-ITD has been shown to induce ROS production. The latter induced DNA 
damages, including oxidization of DNA bases and abasic sites as well as single and 
double-stranded DNA breaks66. In particular, guanine was most sensitive to oxidation 
by ROS due to its low redox potential 67, forming 8-hydroxyguanine (8-oxoG) which 
was a highly mutagenic 68. Increase in ROS was closely related to the NOX family of 
nicotinamide adenine dinucleotide phosphate-oxidases (NAPDH oxidases, NOXs). 
There were 7 isoforms designated as NOX1-5 and dual oxidase 1-2 (DUOX1-2), 
whereas NOX2 and NOX4 are expressed in leukemia 44,69. Each NOX enzymatic 
complex comprised 6 subunits, including a GTPase, usually RAC1 or RAC2 and 5 
phox units (phagocytic oxidase) including gp91phox, p22phox, p40phox, p47phox and 
p67phox70. Mechanistically, a direct association of phosphorylated STAT5 (P-STAT5) 
to RAC1-GDP has been shown to keep the GTPase in its active state, providing a 
possible mechanism for increased ROS generation. In addition, FLT3-ITD signaling 
stabilized p22phox protein via AKT signaling and P-STAT5 can activate transcription 
of NOX4 71,72. The resulting increase in NOX4 protein generates ROS that caused 
damage to genomic DNA. The myeloblast-like 32D cell line expressing FLT3-ITD 
had a higher level of oxidized DNA 8-hydroxy-2’-deoxyguanosine (8-OHdG) and 
DSBs than its wild-type counterparts. Mechanistically, FLT3-ITD increased both 
NOX and p22phox protein expression level. Most importantly, NOX4, p22phox and 
FLT3-ITD protein had been shown to co-localize in the nuclear membrane and were 
essential for the generation of H2O2 that diffused into the nucleus to damage genomic 
DNA72. The reported mechanism of ROS generation via FLT3-ITD signaling is 
illustrated in Figure 1.5.  
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Furthermore, increased ROS might oxidase and hence inactivate a tumour suppressor 
protein-tyrosine phosphatase PTP/DEP-1 which was a negative regulator of FLT3 
signaling. Therefore, ROS may feed forward to FLT3-ITD signaling by inactivating 
its negative regulator. In this context, NOX4 has been shown to be particularly relevant 
73. NOX4 knockdown by shRNA reduced ROS, restored PTP/DEP-1 activity and 
attenuated FLT3-ITD cells proliferation in vitro. A NOX4 inhibitor GKT137831 also 
delayed leukemic progression in FLT3-ITD xenograft mouse model. The FLT3-ITD-
STAT5-NOX4-ROS-PTP/DEP1 axis may provide multiple targets for therapeutic 
inactivation in FLT3-ITD AML.  
 
1.4.2 DSB repair is impaired in FLT3-ITD AML 
In addition to an increase in DNA damage due to increased ROS level, FLT3-ITD 
might impair DDR directly. It has been reported that Ku70 and Ku86, key components 
of the classical NHEJ pathway, were decreased in FLT3-ITD AML 74. On the other 
hand, DNA ligase IIIa (LIG3), a component of the MMEJ pathway, was increased. 
Therefore, FLT3-ITD signaling may affect the choice of DSB repair and skewed it 
from classical to alternative microhomology-based NHEJ. DSB repair via MMEJ 
resulted in larger DNA deletions and insertions than classical NHEJ. However, it still 




Figure 1.5 A schematic diagram showing the reported mechanism of elevated 
intracellular ROS via FLT3-ITD signaling.  
FLT3-ITD signalling led to phosphorylation of STAT5. P-STAT5 subsequently 
translocated to nucleus and activated transcription of NOX4. P-STAT5 was also shown 
to keep RAC1 GTPase in its active GTP bound form. Active RAC1-GTP binding to 
NADPH complex was required for ROS production. FLT3-ITD signaling also 
stabilized p22phox protein via AKT signaling pathway and increased ROS production. 
The elevated ROS production in FLT3-ITD cells increased DNA damage and mis-
repair and caused genomic instability. A low level of ROS was known to enhance 
leukemic cell survival.  
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1.4.3 Targeting DNA repair defect in FLT3-ITD AML 
The DDR pathway has become a target for therapeutic intervention in human cancers, 
exemplified by the use of poly (ADP-ribose) polymerase (PARP) inhibitor in the 
treatment of BRCA mutant breast and ovarian cancers 75,76. PARP detected and bound 
to DNA SSB breakpoint where it initiated synthesis of PAR chain to recruits other 
proteins involved in BER. PARP inhibition impaired BER and led to accumulation of 
SSB. Unrepaired SSB resulted in collapsed replication forks during DNA replication 
and hence the formation of DSB. In cancers with loss-of-function BRCA1/2 mutation 
in which HR was defective, PARPi resulted in excess DSB that recruited error-prone 
NHEJ, causing genomic instability and apoptosis. The use of PARPi to induce 
synthetic lethality has been tested in clinical trials since 2003 77. And a decade later, 
PARP inhibitors Olaparib (2014) and rucaparib (2016) were FDA-approved to treat 
advanced, chemo-resistant ovarian cancer patients with germline BRCA1/2 mutations.  
And later in 2017, niraparib was also approved for treatment of various solid tumours 
including primary peritoneal, ovarian, fallopian tube that are sensitive to platinum 
treatment 78,79. Most importantly, AML carrying t(8;21) and t(15;17) showed down-
regulation of DDR genes and defective DDR and they were extremely sensitive to 
PARPi 41. The aforementioned DDR defects in FLT3-ITD AML and the resulting 
increase in PARP1-depedent MMEJ repair support the proposition that PARP may be 







Chapter 2. Study Objectives 
Since its first description of FLT3-ITD in AML in 1996, much has been learnt about 
its prognostic significance, aberrant signaling and potential as a therapeutic target80. 
In particular, midostaurin was recently approved for treatment of newly diagnosed 
FLT3 mutant AML in combination of conventional chemotherapy and more potent 
and specific FLT3 inhibitors including quizartinib 81, gilteritinib 82 and crenolanib 83,84 
have also been tested and reported in relapsed or refractory settings. However, disease 
relapse remains to be an important cause of treatment failure of FLT3 inhibitor-based 
regimen.  
 
The cumulative evidence about increased ROS production, genomic damage and 
defective DSB repair in FLT3-ITD AML collectively supported the hypothesis that 
DDR defect may provide a new direction for therapeutic targeting. The works 
described in my Ph.D. thesis aimed to ask 3 important questions in this area of AML 
leukemogensis: 
i. Is HR defective in FLT3-ITD AML and what is/are the mechanisms? 
ii. Is PARP inhibitor effective in FLT3-ITD AML and how? 
iii. What is/are the candidate genetic targets that can be exploited in the treatment of 
FLT3-ITD AML in combination with PARP inhibitors?  
 
To address these questions, laboratory platforms have been developed both in HKU 
and KCL and the methodologies were described in the following sections.  
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Chapter 3 Materials and Methods 
3.1 Primary sample processing 
Bone marrow (BM) blood or peripheral blood (PB) collected from AML patients were 
stored at 4 oC prior to processing. The samples were usually processed on the same 
day or no later than the next morning. Ficoll-PaqueTM Plus solution was used to isolate 
the mononuclear cell (MNC) fraction rich in AML blasts by density-gradient 
centrifugation. The processed primary samples were cryopreserved in our liquid 
nitrogen biobank. 
 
The standard operating procedure (SOP) for primary sample processing was as 
following: The whole blood (WB) sample was centrifuged at 1100 rpm for 10 minutes 
at room temperature to isolate the supernatant fraction. The plasma was purified by 
centrifuging the supernatant fraction at 3000 rpm at 4 oC for 10 minutes to remove 
platelet or cell debris and stored at -80 oC. The bottom fraction of WB, containing the 
buffy coat and red cells were diluted with Hanks’ Balanced Salt Solution (HBSS) to 
final volume of 20 mL, carefully laid on 20 mL Ficoll-PaqueTM Plus solution. The 
density-gradient centrifugation was performed at 1200 rpm for 30 minutes at room 
temperature (acceleration = 7, deceleration = 0). The middle layer, containing the 
MNC fraction was isolated by disposable Pasteur pipette and washed twice with 40 
mL of HBSS. The cells were resuspended in HBSS and counted with a 
hematocytometer with 1:1 ratio of Trypan Blue (0.4% solution). For RNA work, 5 
million cells were resuspended in 1 mL TRIzol (Life Tech) and stored at -80 oC for 
subsequent RNA extraction. The remaining MNC were resuspended in pre-cooled 
freezing medium (10% dimethylsulfoxide (DMSO), 20% fetal bovine serum (FBS) 
and 70% HBSS) to final concentration of 20 to 40 million cells/ mL and cryopreserved 
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in Mr. FrostyTM freezing containers overnight at -80 oC overnight prior to the transfer 
and long-term storage in liquid nitrogen tanks.  
 
3.2 Culture and maintenance of cell lines 
3.2.1 Human acute myeloid leukemia cell lines 
Human leukemia cell lines (MOLM-13, MV-4-11 and NOMO-1) were originated 
from DSMZ and ATCC and maintained according to their protocols as listed in 
Appendix 1. 
 
3.2.2 Ba/F3 cell line and its derivatives 
Murine B lymphoid cell line, Ba/F3, and its derivatives transduced with pLKO.1-blast 
(Addgene #26655) carrying FLT3-ITD were generous gifts from Dr. Jerome 
Tamburini in the Institut Cochin, Université Paris Descartes, Paris, France. The cells 
were cultured in RPMI supplemented with 10% FBS and 1% P/S. Murine IL-3 
cytokine (PeproTech) was added to the parental Ba/F3 line at final concentration of 2 
ng/ mL but it was not required for the Ba/F3 FLT3-ITD line.  
 
3.3 In vitro drug treatment 
Ba/F3 parental and Ba/F3 FLT3-ITD cells were seeded in 96-well plate at 0.2 x 105 
cells in 100 μL culture medium and treated with different drug concentrations for three 
days. On day 3, 10 μL PrestoBlue® cell viability reagent (Life Tech) was added into 
each well followed by 4 hours of incubation. The fluorescence signal of PrestoBlue® 
cell viability reagent was measured by FLUOstar OPTIMA microplate reader at 560 
nm excitation and 590 nm emission. 
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Colony forming assay of murine Flt3 ITD/+ x Npm1 c/+ and MLL-AF9 leukemic cells 
was carried out by plating 1-3 x103 cells in MethoCultTM M3234 (Stemcell 
Technology) supplemented with murine cytokines: 20 ng/mL SCF, 10 ng/mL IL-3, 10 
ng/mL IL-6 and 10 ng/mL (PeproTech) together with inhibitors at stated concentration. 
The number of colonies was scored after 7 days.  
 
3.4 RNA extraction and reverse transcription polymerase chain 
reaction 
3.4.1 RNA extraction 
The primary MNC was resuspended in 1 mL TRIzol (Chapter 3.1) and was 
homogenized in a 1mL 29-gauge syringe. The cell lysate was incubated for 5 minutes 
at room temperature. Then, 200 µl of chloroform was added to the tube and incubated 
for 5 minutes at room temperature. The sample was then separated into aqueous, 
interphase and organic phase by centrifugation at 13,400 x g for 15 minutes at 4°C. 
The upper aqueous phase containing RNA was transferred to a new sterile 1.5 ml 
microcentrifuge tube, while the interphase (DNA) and lower organic phase (proteins) 
were discarded. To precipitate the RNA, 500 µl of isopropanol was added and 
incubated at room temperature. RNA pellet was collected by centrifugation at 13,400 
x g for 10 minutes at 4°C, washed with 1 ml of 75% (v/v) ethanol, centrifuged at 
13,400 x g for 5 minutes at 4°C, air-dried for 10 minutes and dissolved in 20 µl of 
DEPC-treated water. Purity and quantity of total RNA were determined by the 
absorbance ratio of 260 nm/280 nm (protein impurity) and 260 nm/230 nm (organic 
solvent impurity) by Thermo Scientific NanoDrop 2000 Spectrophotometer, of which 
most of RNA samples had both ratio greater than 1.8.  
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3.4.2 Reverse transcription polymerase chain reaction 
Extracted RNA was reversed-transcribed to first strand complementary DNA (cDNA) 
using SuperScript II reverse transcriptase kit (Thermo Fisher Scientific). Of note, 1 μg 
of RNA was used for input and 1 μl of random primers (50 ng/ mL) was used for 
amplification. The cDNA was stored at -80 °C until use. 
 
3.5 Real-time quantitative PCR (RT-QPCR) 
The cDNA synthesized in chapter 3.4.2 was diluted 5-fold with RNase-free water as 
template for RT-QPCR using the SYBR Green Select Master Mix (Thermo Fisher 
Scientific) and StepOnePlus Real-Time PCR System (Applied Biosystems). The list 
of primers used for RT-QPCR is listed in Appendix 2. Relative quantification of the 
gene expression was calculated by the comparative algorithm (∆Ct) using β-actin as 
internal control 85. Comparison of relative gene expression was normalized to ∆Ct 
control group. The relative gene expression was calculated as  
2-∆∆Ct = 2- (∆Ct target - ∆Ct control). 
 
3.6 Western Blot  
Cell pellet was lysed with CelLyticTM MT Cell Lysis Reagent (Sigma) with addition 
of protease and phosphatase inhibitors cocktail (Thermo Scientific) to extract soluble 
protein fraction. The extracted protein was mixed with Laemmli loading dye and 
denatured at 95°C for 5 min, separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (7.5, 10 or 12%) and was transferred 
to 0.2 µm nitrocellulose membrane. The blot was then incubated with blocking buffer 
(5% non-fat milk in PBST) for 30 mins and probed with primary antibody overnight 
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at 4°C and secondary antibody at room temperature for 1 hour. Primary and secondary 
antibodies used are listed in Appendix 3. The ECL signal was developed with 
Luminate Forte Western HRP substrate (Millipore) and detected using the ChemiDoc 
MP Imaging System (Bio-Rad). 
 
3.7 Immunofluorescence Microscopy  
At the experimental endpoint, the cells were washed once with 1X PBS and 
resuspended at 1 million/ mL. 100 μL of the cells were cytospun onto glass slides at 
400 g for 5 mins and then fixed with 4% PFA for 15 mins and blocked with 0.5 % 
Triton X-100, 1% BSA in PBS for 30 minutes. The slides were then incubated at 4°C 
overnight with mouse anti- g-H2AX (ser139) (Upstate clone JBW301 #05-636) at 
1:200 dilution overnight. The slides were then washed 3 times with 0.5% Triton X-
100 in PBS and subsequently incubated with 1:200 goat anti-Mouse IgG Alexa Fluor 
488 (ThermoFisher) at room temperature in dark for 1 hour. The slides were then 
washed 3 times with PBS and mounted with coverslips using fluorescence mounting 
medium (Dako).  
 
Fluorescent images were taken with Olympus IX70 (Olympus) using 20X/0.3 NA 
objective and acquired by Olympus DP71 (Olympus) and Olympus DP-BSW basic 
Software. 
 
3.8 Neutral comet assay 
Comet assay was performed using CometAssay® kit (Trevigen) according to the 
manufacturer’s neutral comet assay protocol. The comet images were captured using 
fluorescent microscope (Leica) were analysed using OpenComet 86. 
 
 22 
3.9 General flow cytometry experiments 
All flow cytometry (FACS) were performed with LSRII Fortessa Analyzer (BD 
Biosciences) or FC500 (Beckman Coulter), and data was analyzed using FlowJo 7.6.1 
software (Tree Star, Inc.).  
 
3.9.1 Intracellular reactive oxidative species (ROS) level measurement 
Intracellular ROS was measured using the general oxidative stress indicator CM-
H2DCFDA dye. This dye was cell permeable and was retained in living cells. The 
subsequent oxidation of CM-H2DCFDA in cells yielded a fluorescent adduct that was 
quantified by flow cytometry using the FITC (FL-1) channel.  
 
The CM-H2DCFDA was freshly reconstituted in DMSO at 10 mM immediately 
before each experiment and all the experimental procedure must be kept in dark at all 
time prior to FACS analysis.  
 
At experimental endpoint, cells were washed once with pre-warmed PBS and then 
incubated with 10 μM of the probe in PBS at 37 oC for 30 minutes. The probe was then 
washed off with PBS and incubated again at 37 oC for 30 minutes to recover and to 
ensure the oxidation reaction was completed prior to flow cytometry. 
3.9.2 Immunophenotypic analysis of primary murine cells 
The leukemic mice were first euthanized using CO2 chamber. Total bone marrow cells 
were harvested from femurs and tibias, spleen and liver cells were homogenized and 
filtered with 0.45 μm cell strainer. Red cells were lysed by BD Pharm LyseTM for 5 
minutes on ice in dark and washed with PBS with 2% FBS. The cells were stained 
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with mouse-specific PE/Cy7 anti-CD11b (Mac-1, clone M1/70), PerCp/Cy5.5 anti-
Gr1 (clone RB6-8C5), PE anti-c-Kit (clone 2B8), FITC anti-CD45.1 (clone A20) and 
APC anti-CD45.2 (clone 104) antibodies from BioLegend. All antibodies are used at 
a dilution of 1:200 at 4 °C for 30 mins and analysed by BD LSRII flow cytometer (BD 
Biosciences).  
 
3.10 Lentivirus packaging 
HEK293FT cells were used for packaging of lentivirus. The cells were seeded at 50% 
confluent overnight in 100 mm dish. The next day, 4 μg of the lentiviral packaging 
plasmid pCMV-dR8.91, 4 μg of the envelop plasmid pMD2.G and 7 μg of the transfer 
plasmid were co-transfected using 30 μl of lipofectamine 2000 (Life tech) per 100 mm 
dish. At 8-hour post-transfection, the dishes were replaced with fresh complete 
DMEM medium. 48 hours later, the supernatant was harvested and filtered through a 
0.45 μm filter. The viral particles were concentrated 20-fold by ultracentrifugation at 
25,000 x g for 2 hours at 4 oC. The concentrated lentivirus was aliquoted and stored at 
-80 oC.  
 
3.11 Traffic Light Reporter (TLR) assay  
The TLR assay was developed by Certo et al in 2011 87. The assay consisted of 2 
separate plasmids: pCVL Traffic Light Reporter 1.1 (Addgene #31482) and pCVL 
SFFV d14GFP EF1s HA.NLS.Sce (Addgene #31476), in which both plasmids were 
packaged separately in lentivirus.  
 
The cells were first transduced lentivirally with the TLR plasmids and the next day 
puromycin was added at final concentration of 1 μg/ mL for selection of plasmid 
containing clones for additional 2 days. The cells were then washed with PBS and 
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transduced with pCVL SFFV d14GFP EF1s HA.NLS.Sce lentivirus which expressed 
the I-SceI endonuclease and contained the GFP donor template. Two days post 
transduction, the cells were analysed by FACS.  
 
3.12 DNA damage response (DDR) shRNA library screening 
The cloning protocol of shRNA library, the shRNA hairpin sequences with improved 
knockdown efficiency and Miseq library preparation protocol were provided by Dr. 
Johannes Zuber’s group 88. A brief procedure is described as below.  
 
3.12.1 Cloning of DDR shRNA library plasmids 
The DDR shRNA library consisted of all reported genes with functions annotated to 
DNA damage response pathways from published databases KEGG and REPAIRtoire, 
and review papers 89,90. Multiple shRNA libraries were ordered from Agilent (United 
States) and each gene had 5 unique shRNA hairpins. The mouse DDR shRNA library 
was amplified by library-specific PCR primers with low PCR cycles and cloned into 
lentiviral vector pRRL-GFP-Puro. To ensure complete representation of the hairpin 
library pool, the target number of bacterial colonies was at least 100-fold the total 
number of hairpins. In the case of mouse DDR library with ~1,200 unique hairpins, at 
least 120,000 single colonies were transformed. All colonies were recovered in LB 
broth overnight and plasmid DNA was extracted by Gigaprep (Qiagen).  
 
3.12.2 Experimental Scheme of DDR shRNA library screening 
Mouse DDR shRNA library was packaged into lentivirus and the virus was titrated 
such that less than 30% GFP+ cells post transduction, to ensure that MOI was around 
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1. Twenty million of Flt3 ITD/+ x Npm1 c/+ leukemic cells were transduced with mouse 
DDR shRNA lentivirus for 2 days. GFP+ cells were sorted using BD FACSAria cell 
sorter. 1 x 105 sorted cells were transplanted into sub-lethally irradiated (500 Rads x 
2 doses) CD45.1 SJL mice by intravenous injection. Two weeks post-transplantation, 
the experimental mice were divided into two groups and treated with either 50mg/kg 
Olaparib or vehicle control by intraperitoneal injection 5 days per week for 2 weeks. 
After 4 additional weeks, the mice were euthanized. Total bone marrow cells were 
harvested from femurs and tibias.  
 
3.12.3 Preparation of sequencing library for MiSeq 
Genomic DNA was extracted from cell pellet using QIAamp DNA Mini Kit (Qiagen). 
To keep 1000-fold representation of a pool of 1,200 shRNA at MOI= 1, the total 
amount of DNA input for PCR is 7 µg DNA, assuming 1ng genomic DNA contained 
the DNA from 167 diploid cells. Using PCR primers containing the P5 and P7 adaptor 
sequences and unique barcodes for the Illumina platform, individual DNA samples 
were amplified and barcoded. The purified DNA samples were quantified by Qubit 
and pooled together at 6 nM final concentration. The final DNA samples were 
sequenced using single-read Miseq V2 50 cycle kit (Illumina) with custom sequencing 
primer at READ1 position.  
 
3.12.4 Bioinformatics analysis 
Ms. Claire Lynn, PhD student from Prof. Eric So’s lab in Kings College London 
performed the majority of the bioinformatics analysis, including the processing of the 
raw sequencing data, demultiplexing of sequencing reads, mapping of reads to unique 
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hairpins and the statistical analysis. I performed the final analysis and data 
interpretation.  
 
3.13 In vivo drug treatment of Olaparib and chemotherapy drugs in 
MOLM-13 xenograft model 
8-10 weeks old NOD/SCID/IL2Rg-/- (NSG) mice were sub-lethally irradiated with 250 
cGy 4 hours before transplantation. 1 x 105 of MOLM-13 cells with luciferase reporter 
were resuspended in 150 μL PBS and transplanted into NSG by intravenous injection 
using 29 G syringe. At 4-day post-transplantation, experimental mice were injected 
with 150 mg/kg D-luciferin substrate intraperitoneally and bioluminescence imaging 
were acquired with PE IVIS Spectrum in vivo imaging system (PerkinElmer). The 
dosage and drug delivery method that mimicked the patient “7+3” regimen was based 
on Wunderlich et al 91, which comprised 5 days of cytarabine (25mg/kg) by 
intraperitoneal injection and doxorubicin (1.5mg/kg) by intravenous injection on 
day1-3. Olaparib (25mg/kg) was administrated by intraperitoneal injection for 5 days. 
Post-treatment bioluminescence was taken on the 11th day post-transplantation.  
 
3.14 Statistical analysis 
Unless otherwise specified, data were expressed as means ± standard error of the mean 
(SEM). Comparisons between groups of numerical data were evaluated using 
Student’s t-test. P-values < 0.05, < 0.01 and < 0.001 were considered statistically 
significant, and were represented with asterisk (*), (**) or (***). Survival analysis of 
mouse experiments was performed using the Kaplan-Meier method. Differences in 
survival were determined using log-rank test. Sample size (N) and replicates (n) of all 
experiments were indicated in their corresponding figure legends. 
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Chapter 4. Homologous recombination in FLT3-ITD AML 
was affected with possible mechanistic linkage to down-
regulation of BRCA2.  
4.1 Introduction 
FLT3 is one of the most common mutations in AML 1. Its molecular structure has 
been described in Chapter 1. The JM domain negatively regulates FLT3 function by 
inhibiting phosphorylation. ITD commonly occurs in JM domain, thereby disrupting 
the auto-regulatory function and giving rise to constitutive activation of FLT3 and its 
downstream signaling pathways such as AKT, ERK and STAT5 57. Emerging 
evidences show that FLT3-ITD AML is associated with increased ROS production 
and DNA damage. At the same time, DDR may be defective 70,72,74,92,93 but the 
mechanistic link with particular reference to the relative contribution of HR and NHEJ 
is presently unclear.  
 
4.2 Down-regulation of BRCA2 in FLT3-ITD primary AML samples 
To investigate the link between FLT3-ITD AML and DDR, expression of critical DDR 
genes in primary AML samples was examined by quantitative real-time PCR. The 
study was restricted to de novo and cytogenetically normal AML at diagnosis to avoid 
changes in gene expression secondary to prior chemotherapy. To reduce variation in 
samples, only BM samples were used and all of them showed blast population ≥ 70%. 
A total of 18 FLT3-WT and 13 FLT3-ITD samples were recruited. Six apheresis 
samples from healthy donors who donated peripheral blood stem cell (PBSC) were 
included as control.  
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A panel of genes associated with apical kinase ATM, ATR and DNA-PKcs; DNA 
damage mediators BRCA1, BRCA2 and PARP1; downstream response kinase CHEK1 
and CHEK2 and effectors TP53, were examined. BRCA2 expression was significantly 
down-regulated in FLT3-ITD AML. Those of ATR and P53 were also down-regulated, 
albeit statistically significant (Fig. 4.1). Down-regulation of BRCA2 in FLT3-ITD 
AML was further validated in a microarray database GSE15434 from a multicenter 
study investigating gene expression profiles of normal karyotype AML (WT=148; 
ITD=86) (Fig. 4.2) 94.  
 
4.3 FLT3-ITD signaling was responsible for the suppression of 
BRCA2 expression  
The mechanistic link between FLT3-ITD and DDR genes with particular reference to 
BRCA2 was evaluated in human FLT3-ITD+ AML cell lines MOLM-13 and MV-4-
11 that carried MLL-AF9 and MLL-AF4 fusions respectively. NOMO-1 cell line that 
similarly harbored MLL translocation but wild-type FLT3 was included as control. 
BRCA2 expression was significantly reduced in MOLM-13 and MV-4-11 compared 
with that in NOMO-1, consistent with the observations made in primary samples (Fig. 
4.3).  
 
To ascertain if BRCA2 downregulation was secondary to FLT3-ITD signaling, gene 
expression was examined after treating the 3 cell lines with a FLT3-specific inhibitor 
quizartinib. At a dose up to 5 nM that had been shown to suppress FLT3 signaling in 
MOLM-13 and MV4-11, BRCA2 expression was significantly increased 95. However, 





Figure 4.1 Gene expression profile of DNA repair genes in primary AML 
patients. 
 (A) Quantitative Real Time PCR was performed using complementary DNA (cDNA) 
of leukemic myeloblasts from bone marrow of normal karyotype AML patients. Wild-
type FLT3 (WT): N=18; FLT3-ITD (ITD): N=13. (B) Among all DNA repair genes 
tested, only BRCA2 was significantly down-regulated when compared to normal 










Figure 4.2 BRCA2 expression profile from GSE15434. 
All the samples in this study were normal karyotype AML samples obtained from 
untreated patients at the time of diagnosis. Purified mononuclear cells were collected 
for microarray analysis. Samples were collected from Dresden, Munich and Ulm. The 
data was downloaded from Gene Expression Omnibus under the accession GSE15434. 
The 214727_at probe was used to hybridize and quantity expression of BRCA2. Wild-











Figure 4.3 BRCA2 expression of human AML cell lines. 
Quantitative Real Time PCR was performed using cDNA of human AML cell lines. 
All the cells here harbored MLL-fusion mutations: NOMO1 (MLL-AF9); MOLM-13 
(MLL-AF9); and MV-4-11 (MLL-AF4) respectively. NOMO1 with wild-type FLT3 
serves as the control cell lines. MOLM-13 was heterozygous for FLT3-ITD mutations 




Figure 4.4 Gene expression profile of DNA repair genes in human AML cell lines 
after treatment of FLT3 inhibitor, quizartinib.  
(A) NOMO-1, (B) MOLM-13 and (C) MV-4-11 AML cell lines were treated with 0, 
1 and 5 nM of quizartinib for 4 hours. Relative gene expression was quantified by 
QPCR and normalized to vehicle control. Increase in BRCA2 was observed in FLT3-
ITD AML cell line MOLM-13 and MV-4-11 after quizartinib treatment but not in 
FLT3-WT NOMO-1 control. n=2. * p<0.05. 
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To more clearly define the link between FLT3-ITD signaling and DDR, an isogenic 
Ba/F3 FLT3-ITD cell model was used in which Ba/F3 FLT3-ITD cells survived on 
autonomous FLT3-ITD signaling while parental Ba/F3 cells survived on IL3 that was 
supplemented in culture medium. Consistent with the observations in primary AML 
samples and cell lines, murine Brca2 was significantly down-regulated in Ba/F3 
FLT3-ITD line (Fig. 4.5A) and quizartinib induced a significant increase in these cells 
(Fig. 4.5B).  
 
4.4 Homologous recombination activity was decreased in FLT3-ITD 
cells 
Effective DDR is critical for the maintenance of genomic integrity in cells that are 
exposed to genotoxic agent 96,97. Without timely repair, DNA breaks can cause 
genomic instability and cell death. DSB repair is accomplished by error-free HR that 
utilizes the sister chromatin as a template for DSB repairs and is dependent on intact 
BRCA2 protein that regulates the intracellular location and DNA binding of RAD51 
98-100. Loss-of-function BRCA2 mutation resulted in defective DSB repair and 
predisposes patients to breast or ovarian cancers 101,102. Therefore, the observations of 
BRCA2 down-regulation in FLT3-ITD+ AML supported the proposition that DDR 
may be defective in this AML subtype and it was tested in subsequent experiments. 
 
The Traffic Light Reporter (TLR) assay was used to evaluate the efficiency and repair 
fidelity of DSB in Ba/F3 FLT3-ITD line 87, which allowed a direct measurement of 
the relative efficiency of error-free homologous recombination (HR) and error-prone 












Figure 4.5 Brca2 expression in Ba/F3 FLT3-ITD isogenic model.  
Murine pro-B cell line was lentivirally transduced with coding sequence of human 
FLT3-ITD. (A) QPCR result of Brca2 transcript level shows down-regulation of Brca2 
in Ba/F3 FLT3-ITD line when compares to parental control. n=3; p<0.05. (B) 
Inhibition of FLT3-ITD signaling with AC220 results in rescue of Brca2 expression 
in Ba/F3 FLT3-ITD line by QPCR. n=1.  
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endonuclease. The mutant GFP (containing a premature termination codon, DGFP) 
and mCherry open reading frame (ORF) in the TLR were fused by a ribosome skipping 
sequence (T2A) that allowed translation of 2 distinct polypeptides without forming a 
peptide bond. GFP and mCherry ORF were positioned in different frames and DSB 
was induced at a unique recognition site for endonuclease I-Scel in the mutant GFP 
ORF. If NHEJ repair had occurred, it would place DGFP in frame with mCherry in 1 
out of 3 events, leading to mCherry fluorescence. If HR repair had occurred, the GFP 
donor template that was lentivirally transduced after TLR would replace DGFP in TLR, 
leading to GFP fluorescence (Fig. 4.6). Compared with the parental line control, DSB 
repair by HR was significantly decreased in Ba/F3 FLT3-ITD while DSB repair by 
NHEJ was not significantly different (Fig. 4.7 & 4.8). In summary, the data 
demonstrated that FLT3-ITD down-regulated BRCA2, impaired HR and DSB repair 
fidelity in FLT3-ITD AML.  
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Figure 4.6 Principle of the Traffic Light Reporter (TLR) assay. 
(A) The simplified vector map of the TLR plasmid illustrating the structure of the TLR 
transcript. The open reading frame relative to the initial defective GFP (dGFP) was 
indicated in superscript. (B) I-SceI nuclease cleaved the TLR at the target site and 
induced double-stranded break (DSB). The DSB could be either repaired via the 
homology-directed recombination using the exogenous donor template and 
reconstituted the full GFP sequence and the cells would emit green fluorescence. If 
the DSB underwent non-homologous end joining (NHEJ), one in third chance would 
result in 2bp frameshift and translated an in-frame mCherry protein and emitted red 





Figure 4.7 Representative flow plot of the TLR reporter assay. 
The Ba/F3 parental and FLT3-ITD cells stably expressing the TLR reporter construct 
were lentivirally transduced with a plasmid expressing I-SceI and GFP donor template. 
The transduced cells were analyzed by flow cytometer 2 days post transduction. Top 
left quadrat gated on GFP+ cells: cells underwent HR and bottom right quadrat gated 






Figure 4.8 Statistical analysis of the TLR assay.  
(A) & (B) Quantification of % measured events of GFP+ cells (HR) and mCherry+ 
cells (NHEJ) respectively. (C) Ratio of HR to NHEJ, representing the relative DSB 
repair fidelity. n=3. Error bar=SEM; p-value: * <0.05; *** < 0.001; ns: not significant.  
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Chapter 5. Targeting FLT3-ITD AML with PARP inhibitor  
5.1 Introduction  
Defective DDR plays an important role in the pathogenesis of AML 18. Myeloblasts 
from FLT3-ITD+ AML patients showed a significantly higher level of reactive 
oxidative species (ROS) than AML patients with FLT3 wild type alleles (FLT3-WT) 
93. Elevated level of both cytoplasmic and nuclear reactive oxidative stress (ROS) were 
observed in FLT3-ITD AML cell lines as well as murine cell line transduced with 
FLT3-ITD constructs 71,73,103,104. In particular, decreased NHEJ and increased PARP1-
dependent MMEJ activity resulted in large DNA insertions and deletions74. The data 
from Chapter 3 showed that FLT3-ITD+ cells had BRCA2 down-regulation and 
reduced HR activity, this chapter examined whether drugs targeting DNA repair 
pathways, in particular, PARPi, could be used to intervene the leukemic development 
of FLT3-ITD transformed Ba/F3 cells.  
 
5.2 PARP inhibitors selectively targeted FLT3-ITD AML in vitro by 
cell proliferation assay 
To target key components in DDR, FLT3-ITD AML was treated with a panel of small 
molecular inhibitors targeting ATM, ATR, CHEK1/2 and PARP. Effects on leukemia 
growth in vitro were evaluated by Presto Blue colourimetric assay up to maximum 
plasma concentration reported in patients. Of the 4 inhibitors tested, PARP inhibitor 
Olaparib showed preferential inhibitory effects on Ba/F3 FLT3-ITD over the parental. 
ATM inhibitor KU-55933 also showed a modest but significant preferential effect on 














Figure 5.1 Cell proliferation assay of inhibitors targeting DNA repair proteins. 
Ba/F3 FLT3-ITD cells and the parental control line were treated with inhibitors for 3 
days. The number of viable cells was measured by cell viability dye Presto Blue 
relative to the vehicle control. The inhibitors targeted (A) PARP; Olaparib, (B) ATM; 







5.3 FLT3-ITD cells showed higher basal level of double-stranded 
DNA breaks that was accentuated by Olaparib. 
In this section, the genotoxic effect of PARP inhibition in FLT3-ITD cells was 
examined, predicating on the premise that PARPi should impair SSB repair and cause 
DSB accumulation, driving FLT3-ITD cells to NHEJ pathway for DDR as BRCA2 
expression and HR activity were suppressed in this AML subtype. The error-prone 
NHEJ might induce genomic instability and apoptosis.  
 
Gamma-H2AX (g-H2AX) is a biomarker for DNA double-stranded breaks, of which 
DSBs in the chromatin initiate the phosphorylation of the histone H2AX at serine 139 
25. By immunoblot analysis and immunofluorescence, basal level of g-H2AX was 
higher in Ba/F3 FLT3-ITD cells when compared to control (Fig. 5.2), indicating a 
higher level of basal DSB. Olaparib treatment significantly accentuated DSB as 
demonstrated by an increase in gH2AX immunostaining.  
 
The neutral comet assay, a single cell gel electrophoresis assay to detect genomic DSB 
for single cell, was performed to directly quantify the genomic DNA damage caused 
by FLT3-ITD oncogenic protein and the effects of Olaparib (Fig. 5.4A). The comet 
assay images were analysed by OpenComet (Fig. 5.4B) 86. FLT3-ITD induced higher 












Figure 5.2 Analysis of g-H2AX level in Ba/F3 FLT3-ITD cells treated with 
Olaparib by immunoblot analysis and immunofluorescence microscopy. 
Ba/F3 FLT3-ITD cells and the Ba/F3 control line were treated with of Olaparib. The 
cells were harvested after 24 hours for immunoblot and immunofluorescence analysis. 
(A) Representative immunoblot result with increasing dose of Olaparib at 1 and 2.5 
µM of Olaparib. The (B) Representative immunofluorescence image captured with 





Figure 5.3 Diagrammatic illustration of neutral comet assay analysis using 
OpenComet Software. 
The raw comet image was imported to OpenComet plugin in ImageJ and the analysis 
was run automatically. Individual comet was identified by the Comet Head Finding 
Algorithm as shown in the figure as 1, 2 and 3. The olive circle represented whole 
comet and the regular circle represented comet head. The tail moment was calculated 
as the length of comet tail times tail DNA %. 
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Figure 5.4 Neutral comet assay in Ba/F3 FLT3-ITD cells treated with Olaparib. 
The cells were treated with 1 µM of Olaparib for 24 hours and subjected to neutral 
comet assay to detect DNA double-stranded breaks. (A) Representative comet images. 
White bar = 75 mm. (B) Statistical analysis of comet images using the OpenComet 
software. The double-stranded DNA breaks were quantified by tail moment (% of 




5.4 Elevated ROS level modulated sensitivity of FLT3-ITD to PARP 
inhibitor 
To identify the cause of increased DSB in FLT3-ITD AML, intracellular ROS was 
measured in Ba/F3 FLT3-ITD. The level of ROS was significantly higher in FLT3- 
ITD compared with its parental control (Fig. 5.5). Intriguingly, Olaparib treatment 
accentuated the increase in ROS in Ba/F3 FLT3-ITD cells but not the parental control.  
 
5.5 Combination of PARP inhibitors and chemotherapy  
The result of defective HR repair and anti-leukemic effect of PARPi in FLT3-ITD 
AML suggested that it might be used to sensitize leukemic cells to chemotherapy. The 
effects of Olaparib in combination with chemotherapy were evaluated in MOLM-13 
NSG xenograft model (see Chapter 3.13). Leukemia engraftment was monitored at 
real-time by bioluminescence imaging after intraperitoneal luciferin injection. 
Olaparib in combination with chemotherapy suppressed leukemic growth in vivo (Fig. 


























Figure 5.5 Intracellular ROS measurement of Ba/F3 FLT3-ITD cells treated with 
Olaparib.  
Ba/F3 parental and FLT3-ITD cells were treated with Olaparib for 24 hours and 
followed by loading of ROS detecting probe 2’7’-dichlorodihydro-fluorecein 
diacetate (H2DCFDA). The intracellular ROS level was measured by flow cytometry 
and normalized to Ba/F3 parental vehicle control. n=3, * p < 0.05; *** p < 0.001. 





Figure 5.6 In vivo drug treatment of Olaparib and chemotherapy in MOLM-13 
xenograft model. 
(A) MOLM-13 AML cells transduced with a luciferase reporter were intravenous 
injected into NSG mice. The pre-treatment bioluminescence image was captured at 4-
day post-transplantation. At the 5th day of the experiment, mice were divided into 4 
groups for drug treatment for 5 days. The post-treatment image was taken at 11th day 
post-transplantation. The experiment was terminated due to cytotoxic effect of chemo 
drugs. (B) The graph showing the change in luminescence intensity with individual 
experimental mouse.  
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Chapter 6 Screening of synthetic lethal candidate of DDR 
genes with PARP inhibitors by shRNA library screen 
The works described in the previous chapters has led to identification of PARP 
inhibitor Olaparib as a potential therapeutic agent in FLT3-ITD AML. However, the 
effects of Olaparib were generally modest and more effective regimen comprising 
Olaparib and its therapeutic partners were needed. This could be accomplished by a 




The DDR shRNA library consisted of all reported genes with functions annotated to 
DDR pathways from publications and published databases KEGG and REPAIRtoire 
8,14,15,17,18,89,90. A total of 248 genes were included in this study. The screening was 
performed in collaboration with Dr. Johannes Zuber (Research Institute of Molecular 
Pathology, Vienna) 88. List of clinical trials involving DDR inhibitors was summarized 
in Appendix 4 78. The workflow of the procedure was shown in Figure 6.1.  
 
6.2 Characterization and generation of Flt3ITD Npm1c+ cell line 
To generate murine Flt3 ITD/+ Npm1 c/+ leukemic cell line, spleen cells from Flt3 ITD/+ 
Npm1c/+ double knockin mouse (generously provided by Dr. George S Vassiliou, 
Sanger Institute, UK) were transplanted into recipient mice to develop AML 105. Once 
AML occurred, BM cells were isolated and established into a stable and proliferating 










Figure 6.1 Construction of mouse DDR shRNA library. 
Based on literature review, a total of 248 genes with reported DNA damage response 
were selected. Top 5 hairpins of each gene were selected for oligo synthesis. 
Following the cloning of shRNA library plasmid, the DDR shRNA library was 
packaged into lentivirus for subsequent experiments.  
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recipient mice were shown in Figure 6.2, showing a predominant mature granulocytic 
(Gr-1+/ Mac1+), monocytic (Gr-1-/Mac1+) and immature myelomoncytic (c-kit+) 
populations, resembling the immunophenotype in previous publication 105. Those of 
the AML cell line established in vitro were shown in Figure 6.3. and they were all 
Mac-1+ / Gr-1+ mature granulocytic leukemic cells, indicating successful 
establishment of a Flt3 ITD/ Npm1 c/+ myeloid-lineage leukemic cell line. The in vitro 
effects of Olaparib on their clonogenicity were examined. Olaparib suppressed the 
colony forming ability of the Flt3 ITD/+Npm1 c/+ leukemic cells more significantly than 
the MLL-AF9 transformed AML cells (Fig. 6.4). 
 
6.3 Experimental scheme of DDR shRNA screening in vivo  
The experimental scheme was designed with the purpose of screening for novel 
therapeutic agents that could work synergistically with Olaparib (Fig. 6.5). Flt3 ITD/+ 
Npm1 c/+ AML cells were transduced with lentivirus carrying pRRL-GFP-Puro-mouse 
DDR-shRNA. AML cells that were successfully transduced were purified by FACS 2 
days post-transduction and transplanted into recipient mice intravenously. Two weeks 
post-transplantation, one group of recipient mice were treated with Olaparib (50mg/kg) 
intraperitoneally for 2 weeks and another group received vehicle control (same volume 
of DMSO solvent control) by the same route and for the same duration. All mice were 
euthanized and analyzed 4 weeks after completion of the 2-week treatment or if they 
showed symptoms of debilitation which was most likely related to underlying AML. 
Genomic DNA was extracted from their BM samples and Miseq sequencing library 
was prepared as per protocol from Dr. Johnannes Zuber. The list of DNA samples 
submitted for sequencing was shown in Appendix 5. Diagrammatic representation of 






Figure 6.2 Immunophenotype analysis of leukemic mice transplanted with spleen 
cells recovered from Flt3ITD/+ Npm1c+/+ knockin mouse.  
Representative flow cytometry data of Flt3 ITD/+ Npm1 c/+ leukemic cells gated on 
CD45.2 population of bone marrow (BM), spleen and liver cells of the recipient mice. 
Result showed that the leukemic cells resided in BM were predominantly Mac-1+ / 
Gr-1+ mature granulocytic cells while leukemic cells resided in spleen and liver were 

















Figure 6.3 Immunophenotype analysis of primary murine Flt3 ITD/+ Npm1 c/+ cell 
line. 
Representative flow cytometry data of the in vitro established Flt3 ITD/ Npm1 c/+ 
leukemic cells line. Result showed that the cell line was predominantly Mac-1+ / Gr-








Figure 6.4 Colony formation assay of leukemic cells of MLL-AF9 or Flt3ITD/+ 
Npm1c/+ treated with Olaparib for 5 days in methyl cellulose.  
(A) Relative no. of colonies normalized to vehicle control and (B) Absolute no. of 








Figure 6.5 Experimental scheme of in vivo shRNA library screening. 
The Flt3 ITD/+ Npm1 c/+ leukemic cells were lentivirally transduced with mouse DDR 
library shRNAs. At 48th hours post-transduction, the GFP+ transduced cells were 
sorted out by FACS and 0.1 million of sorted cells were transplanted into each 
recipient CD45.1 SJL mouse. Two weeks post-transplantation, the experimental mice 
were divided into two groups and treated with either 50mg/kg Olaparib or vehicle 
control for 2 weeks. The drug-resistant clones were allowed to recover for 4 additional 
weeks in vivo. The genomic DNA of total bone marrow leukemic cells were harvested, 
together with the pre-transplant samples to prepare sequencing library for Miseq run.  
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Figure 6.6A. Prior to Miseq sequencing, the pooled final PCR product was subjected 
to Sanger sequencing using Illumina P5 adaptor primer to confirm correct 
amplification of shRNA hairpin region, unique barcoding region and custom 
sequencing primer binding site (Figure 6.6B). The sequencing library was sequenced 
by Illumina Miseq platform using Miseq V2 50 cycle kit. 
 
6.4 Basic bioinformatics filtering of the MiSeq run 
Basic bioinformatics analysis, including FASTQC of sequencing run, trimming of 
reads, de-multiplexing and mapping of shRNA hairpins and statistical analysis were 
performed by Ms Claire Lynn. The FASTQC confirmed the 22bp reads of shRNA 
hairpins followed by the common sequencing adapter and unique barcodes (Fig. 6.7). 
With the spiking of 20% PhiX control DNA, the remaining 80% of the reads were 
uniquely mapped to the shRNA library, indicating that the Miseq run was successful.  
 
The mapping of unique shRNA hairpins showed that the starting material, the pRRL-
GFP-puro-mouse DDR shRNA library plasmid (#14), contained all 1240 unique 
mouse DDR shRNA hairpins (Fig. 6.8A). Similarly, most unique hairpins were 
detected in the pre-transplantation samples (#1 & 7) and were mapped to 1235 and 
1228 unique hairpins respectively. The number of unique hairpins was decreased in 
endpoint samples, indicating that cells carrying those hairpins were dropped out 
overtime.  
 
The quality filtered mapped reads of individual samples were shown in Figure 6.8B. 









Figure 6.6 Information of DNA sample for Miseq. 
(A) Diagram showing the final PCR product generated for Miseq sequencing. (B) 
Chromatogram of the final pooled DNA sample by Sanger sequencing using Illumina 








Figure 6.7 FASTQC plot of the Miseq sequencing run. 
The diagram showed the read alignment of pooled sequencing reads with the 20% 
PhiX control DNA filtered out. Starting from read position 1-22 was the unique shRNA 
sequences following by the common sequencing adapter from position 23-50. The 




















Figure 6.8 Alignment result of Miseq run to unique hairpin sequences.  
(A) Result of mapping of reads to unique hairpins. Total number of hairpins in the 
mouse DDR library was 1240. (B) Result of mapping the quality filtered mapped reads. 
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was 1000-fold of the number of total hairpins, i.e. 1.2 x 106 reads. In this study, the 
number of reads of individual samples ranged from 7397 (#11) to 0.46 x 106 (#2) (Fig.  
6.8B). Cutoff for downstream analysis was set to 0.12 x 106 reads. Therefore, sample 
# 8 and 11, with 47,197 and 7,397 mapped reads, were not included for further analysis.  
 
6.5 Dropout analysis of shRNA library screening 
Analysis of shRNA screen was performed using an open-source processing pipeline 
optimized for analyzing pooled library sequencing screens in edgeR106. The overall 
distribution of probability of hairpin dropout was shown in Figure 6.9.  
 
A gene was considered as dropped out if the probability of hairpin dropout (Pdrop) ≥ 
0.6, i.e. 3 out of 5 hairpins of that gene were significantly dropped out (p-value < 0.05) 
compared with pre-transplant samples. There were 206 dropout genes in Olaparib-
treated group and 70 in the vehicle-treated group. To identify genes that were dropped 
out preferentially in Olaparib-treated group, the group specific dropout was examined 
based on the probability of dropout Olaparib minus vehicle-treated (Pdrop of O-V) of 
which the cutoff threshold was set at ≥ 0.6 (Figure 6.10), i.e. at least 3 out of 5 hairpins 
of the same gene were dropped out in the Olaparib-treated group compared with the 
vehicle-treated group.  
 
183 genes were dropped out in both vehicle-treated and Olaparib-treated leukemic 
cells (Fig. 6.10). They were considered candidates with oncogenic potential 
independent of the effects of Olaparib, including genes that were important for cell 






Figure 6.9 Overall distribution of probability of gene dropout in the shRNA 
screen.  
Distribution plots showing the probability of dropout of all murine DDR genes in the 
shRNA screening. Top plot was overall distribution of dropout of comparing in vivo 
vehicle-treated endpoint samples verse pre-transplant samples while bottom plot 






Figure 6.10 Distribution of unique hairpin dropouts. 
(A) Venn diagram showing the number of unique gene dropouts in vehicle-treated 
group (2), Olaparib-treated group (29) and the overlaps gene dropouts (183). (B) The 
plot showing the difference of probability dropout of Olaparib-treated group and 
vehicle-treated group.  
The dropout probability of important DDR genes was listed in Appendix 6. 
Surprisingly, HR genes such as Brca2 were categorized in the common dropout group 
because the baseline cutoff of Pdrop was set at 0.6 (Appendix 7). Nevertheless, all 5 
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hairpins of Brca2 were dropped out in Olaparib-treated group while 3 hairpins were 
dropped out in the control group, demonstrating the effectiveness of targeting Brca2-
down-regulated clones using Olaparib.  
 
29 genes were dropped out specifically in the Olaparib-treated group (Fig. 6.10). They 
were enriched in checkpoint factors and DNA replication factors (Fig. 6.11). For 
instance, members of the Family B Polymerase are involved in nuclear DNA 
replications and they include Polymerase alpha (a), delta (d) and epsilon (e) 
(Appendix 5) 107-109. The Atr (ATM and rad3-related) gene encodes a master regulator 






Figure 6.11 Pie chart of overall distribution of dropout genes categorized by their 
role in DNA damage response pathways.  
Top chart showed the percentage of total DDR library genes sorted by DNA repair 
pathways, and similar distribution was found in the Middle chart: the overlap group. 
The percentage of check point factors and DNA repair genes were increased in 
Olaparib droupout drop (Bottom chart).  
Abbreviations: DR (DNA repair); BER (base excision repair); NER (nucleotide 
excision repair); MMR (mismatch repair); HR (homologous recombination); NHEJ 
(non-homologous end-joining); FA (fanconi anemia); Other DSBR (double stranded 
breaks repair); TLS (translesion repair) 
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Chapter 7. Summary and Discussions 
Despite their diversity of clinicopathologic, cytogenetic abnormalities and genetic 
mutations, current treatment for AML has been uniform 1,3-6. FLT3-ITD is one of the 
most common mutations in cytogenetically normal AML with higher relapse rates and 
poorer overall survivals. Although clinical studies have shown the effectiveness of 
multi-kinase or specific FLT3 inhibitors in clearing myeloblasts from blood and BM, 
the response was invariably transient 61-65. There is an urgent need to develop novel 
effective strategy for this AML subtype. 
 
The research began by the observation that BRCA2 expression was significantly 
suppressed in primary AML samples and human AML cell lines carrying FLT3-ITD 
as well as mouse B-lymphoid Ba/F3 cells transduced with FLT3-ITD, consistent with 
the GSE15434 gene expression data deposited by Dugas’s group in University of 
Münster. BRCA2 was regulated by FLT3-ITD signaling and its expression could be 
restored by a specific FLT3 inhibitor quizartinib. On the other hand, defective HR 
repair was evident by Traffic Light Reporter assay. Increased DSB was demonstrated 
by increased g-H2AX staining as well as the neutral comet assay and was likely 
secondary to an increase in ROS. The results have shed important lights to the 
pathogenesis of FLT3-ITD AML and were of clinical significance to the development 
of therapeutic strategies for this AML subtype.  
 
This study highlighted the importance of defective DDR in the pathogenesis of FLT3-
ITD AML. The results were consistent with published data about defective DDR in 
this subtype, but the underlying mechanisms were reportedly different among studies. 
In this study, it was associated with down-regulation of BRCA2 expression and HR. 
On the other hand, down-regulation of Ku70 and Ku80, key components of classical 
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NHEJ pathway and up-regulation of DNA ligase IIIa, key enzyme in alt-NHEJ 
pathway component, have been reported in both FLT3-ITD AML cell lines and mouse 
Flt3-ITD knockin model 74. Paradoxically, increase in RAD51 expression and HR 
activity have also been reported in FLT3-ITD AML 20,103,113. Very recently, both HR 
and NHEJ, but not the alt-NHEJ pathway, were shown to be dependent on FLT3 
signaling 20. Differences in cell line models and the use of FLT3 inhibitors in terms of 
doses and timing might have contributed to the different observations. These 
discrepancies notwithstanding, our study provided functional readout of HR and 
NHEJ, showing defective HR but not NHEJ in an isogenic Ba/F3 FLT3-ITD cell 
model.  
 
Results arising from this study were of clinical relevance. PARP inhibitors have been 
shown effective in the treatment of BRCA mutant breast and ovarian cancers 75,76, a 
condition known as synthetic lethality in which PARP becomes a therapeutic target 
when DSB repair is defective due to BRCA mutation. Similarly, the observations that 
BRCA2 expression was down-regulated in FLT3-ITD AML supported the proposition 
that PARP inhibitors might be an effective treatment. In fact, Olaparib suppressed 
leukemia cell proliferation and clonogenicity in both Ba/F3 FLT3-ITD and Flt3 ITD/+ 
Npm1c/+ cell line models. Combination of Olaparib and chemotherapy was also 
effective in reducing leukemia growth in vivo based on small number of animals 
studied so far. Intriguingly, treatment of Olaparib further increased the intracellular 
ROS level. There were also emerging evidences that DNA damage could induce ROS 
generation through the H2AX-Nox1-Rac1 pathway 114, uncovering a mechanistic link 
of two dysregulated pathways in FLT3-ITD AML. Therefore, it is possible that the 
PARP inhibitor Olaparib not only increased the level of DSB but also induced more 
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ROS stress, generating a feedback loop to induce more DSB. These observations 
supported a selectively toxic effect of Olaparib towards FLT3-ITD AML cells.  
  
The experimental model developed in this study might provide important foundation 
for larger scale genomic studies. Specifically, an in vivo DDR shRNA library dropout 
screening based on a mouse Flt3ITD/ Npm1c/+ double knockin model was designed to 
identify potential therapeutic targets that might become effective when used in 
combination with Olaparib. First, the nuclear DNA replication Family B Polymerase 
was particularly enriched as dropout candidates. While DNA polymerases are not a 
good target in cancer therapy, antimetabolite such as cytarabine that interferes with 
DNA replication, is widely used as the frontline induction therapy for AML patients. 
This finding further consolidated the proposal of adding Olaparib to standard “7+3” 
chemotherapy for FLT3-ITD AML patients. Second, clinical trials of ATR inhibitors 
are currently in Phase 1/2 for advanced solid tumors as a single agent and in 
combination with chemotherapy, radiotherapy and PARP inhibitors 115. Functional 
studies are ongoing to validate these results and the database will provide leads for 
future mechanistic and clinical studies. 
 
There are a number of limitations in this study. The importance of proving decrease 
in BRCA2 at the protein level was not neglected and multiple optimizations and 
antibodies had been used to detect BRCA2 protein, yet it remained problematic to 
detect this high molecular weight protein in primary AML samples. It is of urgent need 
to obtain this critical data in primary samples. BRCA2 protein level would also be 
compared among human AML cell lines and isogenic 32D and Ba/F3 lines transduced 
with FLT3-ITD. Furthermore, FLT3 inhibitor quizartinib restored BRCA2 expression, 
supporting the proposition that BRCA2 transcription was regulated by FLT3-ITD 
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signaling. Therefore, further experiments using the Tet-on-pLKO doxycycline 
inducible shRNA system (Addgene #21915) would be performed to demonstrate the 
direct link between FLT3 and BRCA2. How FLT3-ITD signaling suppressed BRCA2 
remained unknown and future work by means of transcriptomic and proteomic 
analysis as well as BRCA2 promoter region by chromatin immunoprecipitation 
(ChIP)-PCR and ChIP-seq should be considered. 
 
Another technical challenge in the study of FLT3-ITD AML was the need of robust 
models in both in vitro and in vivo studies. The commonly used model included mouse 
pro-B Ba/F3 cells and 32D myeloblast cells that overexpressed FLT3-ITD oncogene 
and proliferated independent of ambient IL3, with the caveat that they were not strictly 
leukemic 12,70,71,73,74,93,103,104,116,117. Patients-derived FLT3-ITD AML cell lines 
MOLM-13 and MV-4-11 have also been compared with other human AML cell lines 
carrying wildtype FLT3. However, these cell lines might have accumulated various 
mutations during repeated passages and might not truly represent the biology of the 
original AML from which they were derived. Flt3-ITD knockin mouse model has been 
generated by inserting an ITD mutation into the juxtamembrane domain of murine 
Flt3 allele, resulting in a myeloproliferative state 92,118. Concurrent oncogenic events 
could cooperate with Flt3-ITD to develop bona fide AML model in mice. These 
oncogenic events included conditional knockout of Runx1, Dmnt3a and knockin of 
Npm1 type A mutation 105,116,119-122. Thus, the murine Flt3ITD/+ Npm1c/+ leukemic cell 
line was generated for the shRNA screening. Further experiments that include control 
cell lines without FLT3-ITD signaling should be performed to identify FLT3-ITD 
specific targets.  
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In summary, the work described in this thesis demonstrated increased DSB in FLT3-
ITD AML due to increase in ROS production and defective DDR efficiency and 
fidelity due to reduced BRCA2 down-regulation and HR activity (Fig. 7.1). The latter 
was exploited as a potential therapeutic target as evident by the use of PARP inhibitor 
Olaparib, singly or in combination with conventional chemotherapy in this AML 
subtype. This information would become a solid foundation for future mechanistic and 








Figure 7.1. Diagrammatic summary of work.  
ITD mutation in FLT3 receptor caused constitutive activation of FLT3 signaling and 
led to ligand-independent phosphorylation of STAT5. The FLT3-ITD-STAT5 
pathway increased ROS generation which oxidized genomic DNA and hence SSB 
formation. On the other side, FLT3-ITD down-regulated BRCA2 expression and 
impaired the DSB repair via the error-free HR pathway. The inhibition of BER by 
PARPi resulted in accumulation of SSB during DNA replication and thus led to 
formation of DSB. The unrepaired DSB was mainly repaired by error-prone NHEJ 





Appendix 1 Culture conditions of human AML cell lines. 
Cell lines FLT3 status Key mutation Cell passage density Culture medium 
MOLM-13 WT/ITD MLL-AF9 0.3 x 106/ mL RPMI+10% FBS 
MV-4-11 ITD/ITD MLL-AF4 0.3 x 106/ mL IMDM+10% FBS 
NOMO-1 WT/WT MLL-AF9 0.5 x 106/ mL RPMI+10% FBS 
 
 
Appendix 2 List of primers used for RT-QPCR. 
qPCR primer Forward Reverse 
ATM CCAAATCCCTCCACCTGCAT AGAACACACATTGGATAGTGGT 
ATR ACTGCTTGTTATGACAGGGCT GTCCACTCGGACCTGTTAGC 
BRCA1 GTCCCATCTGTCTGGAGTTGA AAAGGACACTGTGAAGGCCC 
BRCA2 AGCACTCCAGATGGCACAATA TTCTTGACCAGGTGCGGTAAA 
CHEK1 AGGGGTGGTTTATCTGCATGG CTGTTGCCAAGCCAAAGTCT 
CHEK2 AAGCCTTAAGACACCCGTGG CGACTAGTAGAAGGCTGGGC 
DNA-PK GAGAAGGCGGCTTACCTGAG AGCGCCCTTATACATTAGCAT 
P53 TGACACGCTTCCCTGGATTG TTTTCAGGAAGTAGTTTCCATAGGT 
PARP1 AGCTCCCAGGAGTCAAGAGT GTCGTTCTGAGCCTTTAGGG 
GAPDH AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA 
mBrca2 AGATAGGCCTGAGACTTCCTT TGTGGTTCATAACCGTGGGG 










Appendix 3 List of antibodies used.  
Antibody Dilution Company 
Rabbit anti-total FLT3 1:500 Santa Cruz Biotechnology, USA 
mouse anti-g-H2AX (ser139) 1:2000 Millipore 
Mouse anti-b-actin 1:5000 Sigma, USA 
 
 
Appendix 4 Clinical trials involving DDR inhibitors 
Target Agent Phase Cancer(s) enrolled Trial identifier 
DNA-PK MSC2490484A I Solid tumors, CLL NCT02316197 
 MSC2490484A I Solid tumors NCT02516813  VX-984 I Solid tumors NCT02644278 
ATM AZD0156 I Solid tumors NCT02588105 
ATR VX-970 ± chemotherapy I Solid tumors 
EudraCT: 2013-
005100-34   I Solid tumors NCT02157792 
  II Ovarian, primary peritoneal or Fallopian tube NCT02595892   I Solid tumors NCT02595931   II Advanced gynecologic cancers NCT02627443 
  I/II Advanced NSCLC, SCLC, Gynae or neuroendocrine NCT02487095   II Advanced urothelial NCT02567409  VX-970 ± RT I Locally advanced HNSCC NCT02567422   I NSCLC brain metastases NCT02589522 
 VX-970 + targeted 
therapy I Solid tumors NCT02723864 
 AZD6738 I Relapsed CLL, PLL, B-cell lymphomas NCT01955668 
 AZD6738 ± 
chemotherapy I 
Solid tumors, HNSCC, 
ATMloss NSCLC, gastric or GOJ 
carcinoma 
NCT02264678 
  I Solid tumors NCT02630199  AZD6738 + RT I Solid tumors NCT02223923 
CHK1 MK8776 (SCH 900776) II Relapsed AML NCT01870596   I Relapsed lymphoma NCT00779584   I Relapsed AML NCT00907517 
CHK1/2 LY2603618 I/II NSCLC NCT01139775 
  I/II Pancreatic carcinoma NCT00839332   II NSCLC NCT00988858   I Solid tumors NCT01296568   I Solid tumors NCT01341457   I Solid tumors NCT00415636  CCT245737 I Solid tumors NCT02797964   I Solid tumors NCT02797977 
 GDC-0575 ± 
chemotherapy I Solid tumors, relapsed lymphoma NCT01564251  LY2606368 II Refractory SCLC NCT02735980   II Ovarian, breast, prostate NCT02203513   II Solid tumors NCT02873975   I Solid tumors NCT01115790   I Solid tumors NCT02778126   I Solid tumors NCT02514603   I Pediatric solid tumors NCT02808650 
 LY2606368 + 
chemotherapy I Relapsed AML, high risk MDS NCT02649764   I Solid tumors NCT02124148 
 LY2606368 + 
targeted therapy I Solid tumors NCT02860780  LY2606368 + RT I Locally advanced HNSCC NCT02555644 
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WEE1 AZD1775 II SCLC NCT02593019 
  I Solid tumors NCT01748825   I Solid tumors NCT02482311   I Solid tumors NCT02610075 
 AZD1775 + 
chemotherapy II Ovarian, TP53mut NCT01357161 
  II Ovarian, TP53mut, or platinum resistant NCT01164995 
  II Ovarian, primary peritoneal, or fallopian NCT02101775   II NSCLC, 1st line NCT02087241   II NSCLC, 2nd line NCT02087176   II NSCLC NCT02513563   II Gastric carcinoma NCT02448329   II HNSCC NCT02196168   I/II Pancreatic NCT02194829   I/II Pediatric solid tumors NCT02095132   I Locally advanced HNSCC NCT02508246   I Solid tumors NCT00648648 
 AZD1775 + targeted 
therapy I Solid tumors NCT02511795    AML, other myeloid malignancies NCT02381548  AZD1775 + RT I/II Pancreatic NCT02037230   I HNSCC NCT02585973   I Locally advanced cervical cancer NCT01958658   I GBM NCT01849146   I Pediatric DIPG NCT01922076 
 AZD1775 + immune 
checkpoint inhibitor I Solid tumors NCT02617277 
BER TRC102 I Solid tumors, lymphoma NCT01851369 
 TRC102 + 
chemotherapy II GBM NCT02395692   I/II Solid tumors NCT02535312   I Solid tumors NCT00692159   I Hematologic malignancies NCT01658319 
  TRC102 + RT I NSCLC NCT02535325 








Appendix 5 Miseq sequencing run samples. 
Seq ID Experiment Type Description 
1 1 in vivo GFP sorted, pre-transplant sample 
2 1 in vivo End point; BM #1; vehicle 
3 1 in vivo End point; BM #2; vehicle 
4 1 in vivo End point; BM #3; vehicle 
5 1 in vivo End point; BM #5; Olaparib 50mg/kg 
6 1 in vivo End point; BM #6; Olaparib 50mg/kg 
7 2 in vivo GFP sorted, pre-transplant sample 
8 2 in vivo End point; BM #1; vehicle 
9 2 in vivo End point; BM #2; vehicle 
10 2 in vivo End point; BM #3; vehicle 
11 2 in vivo End point; BM #4; Olaparib 50mg/kg 
12 2 in vivo End point; BM #5; Olaparib 50mg/kg 
13 2 in vivo End point; BM #6; Olaparib 50mg/kg 





Appendix 6 Candidate dropout gene list specific to Olaparib treatment.  
 
Abberviations: Veh. (vehicle); Ola. (Olaparib); Diff. (difference); DR (DNA repair); 
BER (base excision repair); NER (nucleotide excision repair); MMR (mismatch 
repair); HR (homologous recombination); NHEJ (non-homologous end-joining); FA 














Abberviations: Veh. (vehicle); Ola. (Olaparib); Diff. (difference); DR (DNA repair); 
BER (base excision repair); NER (nucleotide excision repair); MMR (mismatch 
repair); HR (homologous recombination); NHEJ (non-homologous end-joining); FA 
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